CR20140513A - Uracilos sustituidos bicíclicamente y uso de los mismos - Google Patents
Uracilos sustituidos bicíclicamente y uso de los mismosInfo
- Publication number
- CR20140513A CR20140513A CR20140513A CR20140513A CR20140513A CR 20140513 A CR20140513 A CR 20140513A CR 20140513 A CR20140513 A CR 20140513A CR 20140513 A CR20140513 A CR 20140513A CR 20140513 A CR20140513 A CR 20140513A
- Authority
- CR
- Costa Rica
- Prior art keywords
- bicyclically
- uraciles
- replaced
- same
- diseases
- Prior art date
Links
- 230000006806 disease prevention Effects 0.000 abstract 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente solicitud se refiere a derivados de uracilo novedosos sustituidos bicíclicamente, a procedimientos de preparación de los mismos, al uso de los mismos solos o en combinaciones para el tratamiento y/o la prevención de enfermedades y al uso de los mismos para la producción de medicamentos para el tratamiento y/o la prevención de enfermedades
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167231 | 2012-05-09 | ||
| PCT/EP2013/059286 WO2013167495A1 (de) | 2012-05-09 | 2013-05-03 | Bicyclisch-substituierte uracile und ihre verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20140513A true CR20140513A (es) | 2014-12-02 |
Family
ID=48289199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20140513A CR20140513A (es) | 2012-05-09 | 2014-11-07 | Uracilos sustituidos bicíclicamente y uso de los mismos |
Country Status (43)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| KR102351418B1 (ko) * | 2013-11-08 | 2022-01-17 | 바이엘 파마 악티엔게젤샤프트 | 1-(3-메틸-2-옥소-2,3-디히드로-1,3-벤족사졸-6-일)-2,4-디옥소-3-[(1r)-4-(트리플루오르메틸)-2,3-디히드로-1h-인덴-1-일]-1,2,3,4-테트라히드로피리미딘-5-카르복실산의 염 |
| US9695131B2 (en) * | 2013-11-08 | 2017-07-04 | Bayer Pharma Aktiengesellschaft | Substituted uracils as chymase inhibitors |
| EP3066098A1 (de) | 2013-11-08 | 2016-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte uracile und ihre verwendung |
| HK1223610A1 (zh) * | 2013-11-08 | 2017-08-04 | Bayer Pharma Aktiengesellschaft | 取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途 |
| WO2017162661A1 (en) | 2016-03-22 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | 1h-benzo[de]isoquinoline-1,3(2h)-diones |
| EP3338780A1 (de) * | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
| EP3615031A1 (en) | 2017-04-27 | 2020-03-04 | Bayer Aktiengesellschaft | Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| JP2021523201A (ja) | 2018-05-15 | 2021-09-02 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド |
| CN110229067A (zh) * | 2019-06-05 | 2019-09-13 | 南京焕然生物科技有限公司 | 一种2-氨基茚制备方法 |
| CN113811530B (zh) * | 2019-07-03 | 2022-07-19 | 南京明德新药研发有限公司 | 作为糜酶抑制剂的嘧啶酮类化合物及其应用 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| CN111440141A (zh) * | 2020-05-20 | 2020-07-24 | 安徽泽升科技有限公司 | 一种羟甲基取代芳杂环类化合物的制备方法 |
| WO2021252951A1 (en) | 2020-06-12 | 2021-12-16 | Vanderbilt University | Methods of treatment for gastrointestinal motility disorders |
| CN114671878B (zh) * | 2020-12-25 | 2023-08-04 | 广东东阳光药业有限公司 | 取代的含氮双环化合物及其用途 |
| CN114685472B (zh) * | 2020-12-25 | 2024-04-26 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| WO2022135502A1 (zh) * | 2020-12-25 | 2022-06-30 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| TW202339707A (zh) * | 2021-12-06 | 2023-10-16 | 美商普萊萃歐治療公司 | 含雜環的ｌｏｎｐ１抑制劑化合物、用途及方法 |
| EP4504201A1 (en) | 2022-04-05 | 2025-02-12 | Socpra Sciences Santé Et Humaines S.E.C. | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US6114532A (en) | 1998-02-03 | 2000-09-05 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| US6458952B1 (en) | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
| EP1219611A4 (en) | 1999-09-03 | 2003-03-19 | Ajinomoto Kk | NEW PROCESSES FOR THE PRODUCTION OF OXAZEPINE DERIVATIVES |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| GB0021315D0 (en) * | 2000-08-30 | 2000-10-18 | Dainippon Pharmaceutical Co | Heterocyclic compounds and intermediates thereof |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| JP2003017508A (ja) | 2001-07-05 | 2003-01-17 | Nec Corp | 電界効果トランジスタ |
| AR038536A1 (es) | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| JP2003342265A (ja) * | 2002-05-22 | 2003-12-03 | Senju Pharmaceut Co Ltd | トリアゾリジン誘導体およびその医薬用途 |
| EP1569905A2 (en) | 2002-12-06 | 2005-09-07 | Eli Lilly And Company | Inhibitors of monoamine uptake |
| AU2004266536A1 (en) * | 2003-08-22 | 2005-03-03 | Teijin Pharma Limited | Drug containing chymase inhibitor as the active ingredient |
| DE102004004928A1 (de) | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
| EP1735319B1 (en) | 2004-03-26 | 2017-05-03 | MethylGene Inc. | Inhibitors of histone deacetylase |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| WO2006071940A2 (en) | 2004-12-23 | 2006-07-06 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
| WO2006119504A2 (en) | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
| WO2007007161A2 (en) * | 2005-07-08 | 2007-01-18 | Orchid Research Laboratories Limited | Novel bio-active derivatives |
| WO2007120339A1 (en) | 2005-12-19 | 2007-10-25 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| DK1987025T3 (da) | 2006-02-14 | 2009-12-07 | Pfizer Prod Inc | Benzoxazinon og benzoxazepinonoxazolidinoner som antibakterielle midler |
| JO2934B1 (en) * | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| GB0622472D0 (en) | 2006-11-10 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel heterocyclic derivatives |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| CA2683785A1 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| CA2702524A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| NZ589019A (en) * | 2008-05-05 | 2012-10-26 | Merck Frosst Canada Ltd | 3, 4 - substituted piperidine derivatives as renin inhibitors |
| DE102008030091B4 (de) | 2008-06-25 | 2011-03-03 | Resprotect Gmbh | Uracilderivate und deren Verwendung |
| CA2727340A1 (en) | 2008-06-25 | 2009-12-30 | Daiichi Sankyo Company, Limited | Carboxylic acid compound |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
-
2013
- 2013-03-05 UA UAA201413167A patent/UA112897C2/uk unknown
- 2013-05-03 RS RS20160510A patent/RS54901B1/sr unknown
- 2013-05-03 PT PT137204079T patent/PT2847190T/pt unknown
- 2013-05-03 PE PE2014001986A patent/PE20142301A1/es active IP Right Grant
- 2013-05-03 DK DK16154186.7T patent/DK3045456T3/da active
- 2013-05-03 MX MX2018008811A patent/MX367599B/es unknown
- 2013-05-03 WO PCT/EP2013/059286 patent/WO2013167495A1/de not_active Ceased
- 2013-05-03 NO NO16154186A patent/NO3045456T3/no unknown
- 2013-05-03 SG SG10202003175QA patent/SG10202003175QA/en unknown
- 2013-05-03 HU HUE13720407A patent/HUE029366T2/en unknown
- 2013-05-03 AU AU2013258223A patent/AU2013258223B2/en active Active
- 2013-05-03 AP AP2014008096A patent/AP2014008096A0/xx unknown
- 2013-05-03 CA CA2872906A patent/CA2872906C/en active Active
- 2013-05-03 SI SI201330233A patent/SI2847190T1/sl unknown
- 2013-05-03 EA EA201492040A patent/EA030383B9/ru not_active IP Right Cessation
- 2013-05-03 SI SI201330934T patent/SI3045456T1/en unknown
- 2013-05-03 LT LTEP16154186.7T patent/LT3045456T/lt unknown
- 2013-05-03 PL PL16154186T patent/PL3045456T3/pl unknown
- 2013-05-03 HU HUE16154186A patent/HUE035462T2/en unknown
- 2013-05-03 BR BR112014028086-0A patent/BR112014028086B1/pt active IP Right Grant
- 2013-05-03 JP JP2015510754A patent/JP6141414B2/ja active Active
- 2013-05-03 ES ES16154186.7T patent/ES2657315T3/es active Active
- 2013-05-03 DK DK13720407.9T patent/DK2847190T3/en active
- 2013-05-03 MY MYPI2014703273A patent/MY181828A/en unknown
- 2013-05-03 PL PL13720407.9T patent/PL2847190T3/pl unknown
- 2013-05-03 RS RS20180076A patent/RS56784B1/sr unknown
- 2013-05-03 EP EP16154186.7A patent/EP3045456B1/de active Active
- 2013-05-03 KR KR1020147034155A patent/KR102083281B1/ko active Active
- 2013-05-03 EP EP13720407.9A patent/EP2847190B1/de active Active
- 2013-05-03 HR HRP20160796TT patent/HRP20160796T1/hr unknown
- 2013-05-03 NZ NZ701700A patent/NZ701700A/en unknown
- 2013-05-03 US US14/399,945 patent/US9481672B2/en active Active
- 2013-05-03 ES ES13720407.9T patent/ES2581537T3/es active Active
- 2013-05-03 CN CN201380034776.9A patent/CN104395310B/zh active Active
- 2013-05-03 EA EA201790032A patent/EA031222B1/ru not_active IP Right Cessation
- 2013-05-03 MX MX2014013571A patent/MX357712B/es active IP Right Grant
- 2013-05-03 CN CN201710219097.9A patent/CN106983751B/zh active Active
- 2013-05-03 PT PT161541867T patent/PT3045456T/pt unknown
- 2013-05-08 UY UY0001034797A patent/UY34797A/es active IP Right Grant
- 2013-05-08 AR ARP130101600A patent/AR090994A1/es active IP Right Grant
- 2013-05-08 JO JOP/2013/0144A patent/JO3290B1/ar active
- 2013-05-08 TW TW102116308A patent/TWI579278B/zh active
- 2013-05-08 TW TW106105676A patent/TWI635085B/zh active
- 2013-05-08 SA SA113340533A patent/SA113340533B1/ar unknown
-
2014
- 2014-11-02 IL IL235438A patent/IL235438A/en active IP Right Grant
- 2014-11-06 CU CU2014000129A patent/CU20140129A7/es unknown
- 2014-11-07 PH PH12014502496A patent/PH12014502496B1/en unknown
- 2014-11-07 ZA ZA2014/08146A patent/ZA201408146B/en unknown
- 2014-11-07 CR CR20140513A patent/CR20140513A/es unknown
- 2014-11-07 CL CL2014003031A patent/CL2014003031A1/es unknown
- 2014-11-07 EC ECIEPI201426138A patent/ECSP14026138A/es unknown
- 2014-11-07 TN TN2014000470A patent/TN2014000470A1/fr unknown
- 2014-11-07 CO CO14246970A patent/CO7131375A2/es unknown
- 2014-11-07 DO DO2014000255A patent/DOP2014000255A/es unknown
-
2016
- 2016-07-06 CY CY20161100636T patent/CY1118900T1/el unknown
- 2016-10-07 US US15/288,968 patent/US9949977B2/en active Active
- 2016-10-07 US US15/288,982 patent/US9949978B2/en active Active
-
2017
- 2017-05-02 JP JP2017091842A patent/JP6367421B2/ja active Active
- 2017-08-10 IL IL253950A patent/IL253950B/en active IP Right Grant
- 2017-11-22 AU AU2017265047A patent/AU2017265047B2/en active Active
-
2018
- 2018-01-23 HR HRP20180125TT patent/HRP20180125T1/hr unknown
- 2018-01-24 CY CY20181100095T patent/CY1119840T1/el unknown
- 2018-03-05 US US15/912,185 patent/US10300062B2/en active Active
-
2019
- 2019-04-02 US US16/373,487 patent/US20200061063A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20140129A7 (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| UY34306A (es) | Pirimidinas condensadas sustituidas y su uso | |
| CU20140082A7 (es) | Pirimidinas y triazinas fusionadas sustituidas y sus uso | |
| UY34918A (es) | Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso | |
| CR20120596A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| NI201400108A (es) | Compuestos de heterociclilo | |
| UA115677C2 (uk) | ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ | |
| CR20130008A (es) | Anillos condensados de pirimidinas y triazinas y su uso para el tratamiento y/o profilaxis de enfermedades cardiovasculares | |
| CO6771409A2 (es) | Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso | |
| UY35241A (es) | Compuestos antivirales | |
| UY35652A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
| UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
| UY32052A (es) | 5-aminopirazoles sustituidos y uso de los mismos | |
| CR20140435A (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| UY35746A (es) | Derivados de fenilalanina sustituidos | |
| ES2421956A1 (es) | Nueva forma cristalina de sulfato de sitagliptina | |
| CR20160155A (es) | Tienouracilcarboxamidas cíclicas y usos de las mismas | |
| UY35745A (es) | Derivados sustituidos de fenilalanina | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
| UY35610A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| CR20150160A (es) | Derivados de macrólidos, su preparación y su uso terapéutico | |
| EA201400786A1 (ru) | Карбоциклические нуклеозиды, их фармацевтическое применение и композиции | |
| DOP2013000284A (es) | Derivados de pirazol útiles como inhibidores de aldosterona sintasa | |
| CU20100260A7 (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos |